Non-small cell lung cancer
Conditions
Interventions
Observation group:None
Sponsors
Shanghai Pulmonary Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Histologically or cytologically confirmed stage IIIb-IV NSCLC or postoperative recurrent NSCLC; 2.ALK positive, and the test results were based on RT-PCR /FISH /IHC /NGS methods in hospital laboratories or testing institutions; 3.Treated with Lorlatinib; 4.Age >=18; 5.Follow-up after receipt of Lorlatinib; 6.Voluntarily enrolled in this study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Any evidence of severe or uncontrolled systemic illness, including uncontrolled hypertension and active bleeding, active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV); 2.The patient was complicated with other malignant tumors and received other anti-tumor therapy during the treatment of loratinib.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of management measures for Ce-n-t-r-al Ne-r-v-o-us Sy-s-t-em adverse events occurring after loratinib treatment on AE; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of central nervous system (CNS) adverse events (AEs) associated with lorlatinib in real world study; | — |
Countries
China
Contacts
Public ContactChunxia Su
Shanghai Pulmonary Hospital
Outcome results
None listed